ELSEVIER

Contents lists available at ScienceDirect

Translational Oncology

journal homepage: www.elsevier.com/locate/tranon



Corrigendum

Corrigendum to "PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor" [Volume 14, Issue 9, September 2021, 101152]

Satoko Koga ^{a,b}, Hideya Onishi ^{a,*}, Shogo Masuda ^a, Akiko Fujimura ^a, Shu Ichimiya ^{a,b}, Kazunori Nakayama ^{a,b}, Akira Imaizumi ^a, Kenichi Nishiyama ^{b,c}, Masayuki Kojima ^{b,c}, Kei Miyoshi ^b, Katsuya Nakamura ^d, Masayo Umebayashi ^e, Takashi Morisaki ^e, Masafumi Nakamurab ^b

^a Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

^b Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

^c Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

^d Department of Respiratory Surgery, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan

^e Fukuoka General Cancer Clinic, Fukuoka, Japan

The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line "autocrine"→"autologous". The authors would like to apologise for any inconvenience caused.

https://doi.org/10.1016/j.tranon.2022.101344



DOI of original article: https://doi.org/10.1016/j.tranon.2021.101152. * Corresponding author.

E-mail address: ohnishi.hideya.928@m.kyushu-u.ac.jp (H. Onishi).